In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOS. ...read more
Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the...read more
Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the...read more
Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday.
The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15....read more
US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOS. ...read more
Cancer biotech Harpoon Therapeutics prices $76 million IPO at $14 midpoint
Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the...read more
US IPO Week Ahead: 2 billion-dollar biotechs in a 4-IPO week
Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the...read more
Immuno-oncology biotech Harpoon Therapeutics sets terms for $76 million IPO
Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15....read more